Bio-Techne TECH Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 64.8%-1.6pp | 66.4%-1.3pp | 67.7%-0.7pp | 68.4%— | |
| Free cash flow margin | 21%+0.7pp | 20.4%+1.4pp | 19%-6.3pp | 25.4%-7.7pp | |
| Efficiency | |||||
| Asset turnover | 0.5×0.0× | 0.4×0.0× | 0.5×0.0× | 0.5×— | |
| Inventory turnover | 2.3×+0.1× | 2.2×-0.1× | 2.3×-0.4× | 2.7×— | |
| Liquidity | |||||
| Current ratio | 3.5×-0.4× | 3.9×-1.0× | 4.8×+1.4× | 3.4×+0.1× | |
| Quick ratio | 2.4×-0.4× | 2.7×-0.8× | 3.5×+0.9× | 2.6×+0.1× | |
| Cash ratio | 0.9×0.0× | 1×-0.5× | 1.4×+0.4× | 1×-0.3× | |
| Leverage | |||||
| Debt-to-equity | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×-0.1× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $12.01-6.6% | $12.87+5.9% | $12.15+17.2% | $10.37+7.4% | |
| Valuation | |||||
| Market capitalization | $7.84B-30.5% | $11.27B-12.7% | $12.91B-5.1% | $13.6B-23.1% | |
| Enterprise value | $8.12B-29.6% | $11.54B-12.5% | $13.18B-4.2% | $13.75B-23.2% | |
| Price / sales | 6.4×-3.3× | 9.7×-1.6× | 11.4×-0.9× | 12.3×-6.7× | |
| Price / book | 4.1×-1.4× | 5.4×-1.1× | 6.6×-1.4× | 8×-3.3× | |
| EV / sales | 6.7×-3.3× | 10×-1.6× | 11.6×-0.8× | 12.4×-6.8× | |
| Free cash flow yield | 3.3%+1.2pp | 2.1%+0.4pp | 1.7%-0.4pp | 2.1%+0.3pp | |
| Dividend yield | 0.6%+0.2pp | 0.4%+0.1pp | 0.4%0.0pp | 0.4%+0.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Bio-Techne's profit margins?
- Bio-Techne (TECH) runs a 65.0% gross margin and a 14.2% operating margin, with a 10.9% net margin.
- Where do Bio-Techne's ratios come from?
- Every ratio is computed from Bio-Techne's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
